Imbach P, Kühne T
Univ. Children's Hospital, Basel, Switzerland.
Vox Sang. 1998;74 Suppl 2:309-14. doi: 10.1111/j.1423-0410.1998.tb05436.x.
Immune thrombocytopenic purpura ITP is characterized by early platelet destruction due to an imbalanced immune response. In acute ITP, a transient increase of HLA-DR molecules has been detected while in individuals with chronic ITP, in addition, increased serum concentrations of IL-2 and other cytokines reflecting in vivo T-cell activation have been observed. Clinically, the hemorrhagic manifestation of ITP rather than the platelet count should define the indication for active intervention. In a staging system a patient with stage III has bleeding signs and platelet counts below 10 or 20 x 10(9)/L and needs treatment, a patient with stage II should be treated on an individual level (prevention of bleeding) and a patient with stage I (no bleeding, platelet count above 50 x 10(9)/L) should be observed only.
免疫性血小板减少性紫癜（ITP）的特征是由于免疫反应失衡导致血小板早期破坏。在急性ITP中，已检测到HLA - DR分子短暂增加，而在慢性ITP患者中，还观察到反映体内T细胞活化的血清IL - 2和其他细胞因子浓度升高。临床上，ITP的出血表现而非血小板计数应确定积极干预的指征。在一个分期系统中，III期患者有出血体征且血小板计数低于10或20×10⁹/L，需要治疗；II期患者应根据个体情况进行治疗（预防出血）；I期患者（无出血，血小板计数高于50×10⁹/L）仅需观察。
